Realeve Developed New Pulsante® Micro-neuromodulation System to Treat Central Nervous System Disorders

Realeve developed new Pulsante® micro-neuromodulation system to revolutionise stroke treatment and improve the lives of patients in various neurological conditions.

Pulsante® micro-neuromodulation system is an implantable device that stimulates the sphenopalatine ganglion (SPG). When used in conjunction with hyperbaric oxygen therapy, it has the potential to significantly improve blood circulation in stroke patients, thereby reducing brain damage and optimising their neurological recovery.

The Pulsante system comprises of a miniature bioactive implant that is inserted through a minimally invasive oral procedure, leaving no discernible scars.

This implant seamlessly pairs with an external, handheld controller designed to stimulate the sphenopalatine ganglion (SPG), a neural hub that governs the autonomic nervous system, offering potential benefits across various neurological conditions.

This precisely targeted therapy not only alleviates pain but also has the capacity to augment blood flow and enhance the delivery of medications to the central nervous system.

Unlike traditional implants like pacemakers, cardiac devices, and insulin pumps that rely on conventional batteries which pose various challenges, among these the most significant is the inevitable battery depletion, which in turn necessitates further surgical interventions.

The Pulsante handheld remote control device wirelessly powers the implant, enabling seamless two-way communication and wireless system updates. This new technology promises to deliver precise and long-lasting relief, greatly enhancing the overall well-being of patients.